# Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

> **NCT01026337** · — · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 43 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **GENETIC:** mutation analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging
- **DRUG:** sunitinib malate
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01026337
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2015-12
- **Final completion:** 2018-11
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026337, "Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01026337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*